Literature DB >> 20616695

High prevalence of reduced bone mineral density in primary HIV-1-infected men.

Marlous L Grijsen1, Saskia M E Vrouenraets, Radjin Steingrover, Paul Lips, Peter Reiss, Ferdinand W N M Wit, Jan M Prins.   

Abstract

OBJECTIVE: To assess the bone mineral density (BMD) in a cohort of men with primary HIV-1 infection (PHI).
METHODS: Thirty-three men with PHI had a dual-energy X-ray absorptiometry (DXA) of the lumbar spine, femoral neck and total hip. Osteopenia and osteoporosis were defined according to WHO criteria as T-scores between -1 and -2.5 and -2.5 or less, respectively. The association between clinical and laboratory parameters and BMD was investigated using multivariable linear regression analysis.
RESULTS: Mean age was 38 (SD 9) years and mean body mass index (BMI) 22.7 (SD 3.3) kg/m. Twenty-four men (73%) had a negative or indeterminate Western blot, 32 men (97%) were combination antiretroviral therapy-naive. Mean plasma HIV-1 RNA was 5.0 (SD 1.2) log10 copies/ml. Mean lumbar spine T (-0.8, SD 1.3, P = 0.001) and Z-scores (-0.7, SD 1.3, P = 0.004) and femoral neck T-score (-0.5, SD 0.9, P = 0.003) were significantly lower compared to the reference population. 15/33 men (45%) had osteopenia and 2/33 (6%) osteoporosis. Markers of bone turnover did not differ between patients with or without osteopenia/osteoporosis. Age was negatively associated with femoral neck (beta-coefficient = -0.05, P < 0.001) and total hip T-scores (beta = -0.03, P = 0.04). BMI was associated with lumbar spine (beta = 0.3), femoral neck (beta = 0.2) and total hip (beta = 0.2) T-scores (P < 0.001) and thyroid-stimulating hormone (TSH) with lumbar spine (beta = 0.5, P = 0.045) and femoral neck T-scores (beta = 0.4, P = 0.005). Increased plasma viral load was associated with lower total hip T-scores (beta = -0.2, P = 0.02).
CONCLUSIONS: Reduced BMD was prevalent in PHI men and was associated with increased age, lower BMI and TSH levels, and higher levels of HIV-1 viremia.

Entities:  

Mesh:

Year:  2010        PMID: 20616695     DOI: 10.1097/QAD.0b013e32833c93fe

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

2.  Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study.

Authors:  D Santi; B Madeo; F Carli; S Zona; G Brigante; F Vescini; G Guaraldi; V Rochira
Journal:  Osteoporos Int       Date:  2015-10-28       Impact factor: 4.507

3.  Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

Authors:  Julie J Kim-Chang; Lorena Wilson; Cliburn Chan; Bernard Fischer; Guglielmo Venturi; Maureen M Goodenow; Grace Aldrovandi; Thomas J Weber; John W Sleasman
Journal:  AIDS Res Hum Retroviruses       Date:  2019-06-27       Impact factor: 2.205

4.  Low bone mineral density and associated risk factors in HIV-infected patients.

Authors:  Cristina-Emilia Chiţu-Tișu; Ecaterina-Constanţa Barbu; Mihai Lazăr; Daniela Adriana Ion; Ioana Anca Bădărău
Journal:  Germs       Date:  2016-06-01

5.  Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Authors:  D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

6.  Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss.

Authors:  Brigitte Raynaud-Messina; Lucie Bracq; Maeva Dupont; Shanti Souriant; Shariq M Usmani; Amsha Proag; Karine Pingris; Vanessa Soldan; Christophe Thibault; Florence Capilla; Talal Al Saati; Isabelle Gennero; Pierre Jurdic; Paul Jolicoeur; Jean-Luc Davignon; Thorsten R Mempel; Serge Benichou; Isabelle Maridonneau-Parini; Christel Vérollet
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

Review 7.  Bone health in HIV and hepatitis B or C infections.

Authors:  Emmanuel Biver; Alexandra Calmy; René Rizzoli
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-07       Impact factor: 5.346

8.  Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A Carr; B Grund; J Neuhaus; A Schwartz; J I Bernardino; D White; S Badel-Faesen; A Avihingsanon; K Ensrud; J Hoy
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

9.  Bone Loss in HIV Infection.

Authors:  Caitlin A Moran; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Curr Treat Options Infect Dis       Date:  2017-02-23

10.  Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

Authors:  Jeannie S Huang; Michael D Hughes; Sharon A Riddler; Richard H Haubrich
Journal:  HIV Clin Trials       Date:  2013 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.